A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma
A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral vorinostat in patients with malignant lymphoma.
Inclusion Criteria:
Exclusion Criteria: